Dataset opportunity
Biossusa — Image Dataset Opportunity
Moderate image dataset held by Biossusa, usable for Computer Vision and Multimodal Pretraining.
Score
47.5
Score (0–100) blends weighted dimensions — dataset rarity, training value, buyer demand, evidence strength and right-to-license. 70+ is deal-ready. See the scored dimensions below for the breakdown.Confidence
63%
Action
Annotation Program
The recommended deal structure for this dataset: Acquire (full buyout), License (paid usage rights), Data Sharing Agreement (controlled access, no transfer of ownership), Partnership (co-development) or Annotation Program (labeling). Chosen from data ownership, licensing complexity and accessibility.Market size (indicative estimate)
Global Digital Pathology market = $1.5B in 2025, CAGR 8.6% (2026-2033).
Lineage
How this lead was derived
The signal-first chain, end to end: recent external signals → qualified niche → resolved data-holder → site verification → scored opportunity. Every lead is explainable.
Profile
Dataset profile
Type
Image Dataset
Modality
Image
Sector
healthcare
Volume
Moderate
Freshness
Periodic
Rarity
Low (commodity)
Accessibility
Partial
Legal
Owned by the company — licensing rights to clarify
Buyer persona
Computer-vision labs & foundation-model teams
Biossusa possesses a substantial Image Dataset composed of high-quality Immunohistochemistry (IHC) and Immunofluorescence (IF) images. This data, derived from proprietary antibody validation records, is directly applicable for training and validating Computer Vision algorithms for automated tissue analysis, biomarker discovery, and diagnostic assistance in pathology.
This type of data serves the global Digital Pathology market, which was valued at USD 1.5 billion in 2025 and is projected to grow at a CAGR of 8.6% through 2033. [1] While access requires navigating IP diligence tied to physical antibodies and the sensitivity of tissue origins, the rarity and high-resolution quality of these validation-specific images represent a crucial asset for AI developers aiming to build next-generation diagnostic tools. ⚠ Diligence (valuable data, access to negotiate): Proprietary validation datasets (IHC/IF images) are partially public but raw high-resolution files remain internal.; Data is tied to physical biological assets (antibodies), requiring technical diligence on IP ownership of validation results.; Potential sensitivity regarding tissue source origins in validation records. · corporate: independent.
Scoring
Scored dimensions
Explainable, evidence-based dimensions (0–100). The radar shows the investment axes.
This evidence collectively proves Biossusa holds a significant dataset derived from over 300,000 products, centered on immunohistochemistry (IHC) and microscopy images. This data is a critical asset for computer vision labs building models for the rapidly expanding digital pathology market, which is projected to reach $1.5 billion by 2025. The dataset's scale and validation for tissue-level interpretation enable the training of sophisticated AI for pathway analysis and diagnostics, meeting a clear and growing demand.
See dimension details ↓- Dataset Specificity66
dominant 'image_collection', sector healthcare, 1 specific types
How sharply the data targets a specific, hard-to-substitute domain or task. Niche, well-defined data scores higher than generic. - Dataset Rarity34
proprietary domain data (open lowers rarity)
How scarce and proprietary the data is. Unique domain data scores high; openly available data lowers it. - Dataset Volume64
5 evidence hits
Apparent scale of the data, inferred from the number of evidence hits and any explicit volume mentions. - Dataset Freshness62
API/open (current)
How current the data stays — real-time/streaming scores highest, periodic dumps lower. - Training Value64
fit for Computer Vision
How useful the data is for the target AI use-case — its fit for model training or fine-tuning. - Buyer Demand85
AI buyer demand is high, driven by the rapid growth of the Digital Pathology market, which is expanding at an 8.6% CAGR and requires high-quality, specific image data for model training. [1]
How strongly AI builders and companies are likely to want this data, based on market signals. - Legal Accessibility68
open/API access
How legally easy the data is to obtain and use — open/API access scores high; PII or regulated data scores low. - Acquisition Feasibility84
medium difficulty, independent
How realistic it is to actually obtain the data, given access difficulty and the holder's corporate structure. - Evidence Strength86
5 evidence types, 5 hits
How solid the proof is that the company holds this data — diversity of evidence types and number of hits. - Right to License70
ownership=company_owned, licensing=rights_unclear
Whether the company can legally license the data out — based on ownership and licensing complexity. - Corporate Independence90
independent
Whether the holder can decide alone — an independent company scores higher than a subsidiary of a large group. - Data Orientation22
0 data-appetite signals (0 types)
How actively the company invests in data, measured by its data-appetite signals (hires, products, APIs…). - Dormant Data Surplus92
surplus=high — proprietary data beyond what's already monetised
Volume and value of proprietary data this company holds BEYOND what it already monetises — the dormant surplus we can unlock. A company can sell some insights AND still sit on a far larger dormant asset. - ICP Audit58
⚠ review — The company's core business is developing and selling biological research reagents like antibodies and ELISA kits, which are intelligence products for researchers, making it a bad fit. Issues: Company's core business is selling research tools and reagents (antibodies, proteins, ELISA kits), which are a form of intelligence/analytics product for the li; The company is already a product vendor for the same market (biomedical research) that would use the data, not a holder of dormant data from an unrelated operat; The prompt's mention of an 'Image Dataset Opportunity' is misleading; their business is selling the reagents that produce the images, not the images themselves
- Deep Qualification90
✓ pass — Biossusa is a data_holder selling antibodies and other research reagents. It generates a valuable proprietary dataset of IHC/IF images as a byproduct of its internal product validation, making it a strong target. Legal terms for data resale are unclear, but a recent AI-related partnership indicates data-awareness.
Evidence
Dataset evidence & lineage
What the typed evidence proves the company holds — reframed for clarity and set against the market.
Developer portal
Company materials establish Biossusa as a primary antibody developer and manufacturer, indicating direct control over the data generation process and its associated provenance.
Downloads / exports
The company offers downloadable product catalogs, providing structured tabular data that can be used to label and enrich the corresponding immunohistochemistry image sets for model training.
Image collection
The holder publicly claims a collection derived from over 300,000 products, with images validated for immunohistochemistry (IHC) and other key computer vision applications in pathology.
business_records
Business and product documents confirm the underlying products are IHC-validated and designed for dependable tissue-level interpretation, directly aligning with the quality requirements for training diagnostic AI.
Knowledge base / docs
A knowledge base containing over 26,000 publications provides a rich source of unstructured text that can be linked to image data, enabling the development of powerful multimodal models.
Marketplace
Dataset details
Detailed schema & sample available on access request.
Want this data?
Request access — we broker a secure deal room. Operator-reviewed, no automatic sharing.
This listing was generated automatically from public signals. It is not verified, and we are not affiliated with this company.
Coverage
Scanned sources
Deliverable
Premium dataset report
Biossusa Image — a Moderate image dataset (Image modality) in the healthcare domain. Primary AI use-case: Computer Vision. Market signal: Global Digital Pathology market = $1.5B in 2025, CAGR 8.6% (2026-2033) (source: Grand View Research). Investment score 47.5/100 (confidence 0.63). Recommended action: Annotation Program.
From the marketplace
Explore live data opportunities
Ablemedicaldevices — 工业运营数据集机会
View opportunity →医疗保健13Therapeutics — 医疗影像数据集机会
View opportunity →医疗保健Comprehensivesleepcare — 医疗影像数据集机会
View opportunity →